4//SEC Filing
Hayes Christopher G. 4
Accession 0001415889-25-008505
CIK 0001660334other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 6:45 PM ET
Size
8.1 KB
Accession
0001415889-25-008505
Insider Transaction Report
Form 4
Hayes Christopher G.
CHIEF LEGAL OFFICER
Transactions
- Award
Employee Stock Option (right to buy)
2025-03-14+250,000→ 250,000 totalExercise: $0.89Exp: 2035-03-14→ Common Stock (250,000 underlying) - Sale
Common Stock
2025-03-17$0.65/sh−4,315$2,805→ 176,458 total
Footnotes (3)
- [F1]Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6378 to $0.6605 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]50% of the total shares subject to the option shall vest on each of March 14, 2026 and March 14, 2027, subject to the Reporting Person's continuous service through such vesting date.
Documents
Issuer
Verrica Pharmaceuticals Inc.
CIK 0001660334
Entity typeother
Related Parties
1- filerCIK 0001805359
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 6:45 PM ET
- Size
- 8.1 KB